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Background: The aim of the current study was to quantify the burden of peripheral arterial disease (PAD) with respect to
health-related quality of life, work productivity and activity impairment, and healthcare resource utilization.
Methods: Data were obtained from the 2010 EU National Health and Wellness Survey (NHWS), which included
participants from France, Germany, Italy, Spain, and the UK (5EU, N = 57,805) as well as the 2010 US NHWS (N = 75,000).
The NHWS is an annual, cross-sectional, self-administered Internet survey which employs a stratified random sampling
frame to match the age and gender characteristics of the NHWS sample with known population statistics. Participants
who self-reported a diagnosis of PAD were compared with participants who did not self-report a diagnosis of PAD on
health-related quality of life (mental and physical component summary scores and health utilities from the Short
Form-12v2), work productivity and activity impairment (Work Productivity and Activity Impairment questionnaire), and
healthcare resource use in terms of the number of physician visits, emergency room visits, and hospitalizations in the past
six months through regression modeling adjusting for demographics and health characteristics.
Results: A total of 743 (1.29%) and 777 (1.04%) participants self-reported a diagnosis of PAD in the 5EU and US,
respectively. After adjusting for demographics and health characteristics, patients with PAD reported worse health-related
quality of life, as measured by health utilities (5EU: 0.66 vs. 0.70; US: 0.66 vs. 0.72; all p < .05), greater overall work
impairment percentage (5EU: 38.27% vs. 27.48%; US: 23.89% vs. 14.26%) and greater healthcare resource use compared to
participants without PAD (all p < .05).
Conclusions: These results suggest a significant burden for patients with PAD in both the 5 EU countries and the US with
respect to both quality of life and economic outcomes. Improved management of these patients may have profound
effects from both patient and societal perspectives.
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Peripheral arterial disease (PAD) is a condition which re-
sults from atherosclerosis in the abdomen or lower ex-
tremities [1]. Pain in the muscles of the legs during
walking, known as intermittent claudication, is the most
common clinical presentation [2]. Left untreated, PAD
can progress to chronic pain in the legs and eventually to
non-healing wounds, gangrene, and limb loss [3]. Morbid-
ity and mortality risk among PAD patients is high. Caro
and colleagues (2005) examined 16,440 patients in Canada
and found that within an average of 6 years following* Correspondence: marco.dibonaventura@kantarhealth.com
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reproduction in any medium, provided the ordiagnosis, 9.7% of patients had a stroke, 9.5% had a myo-
cardial infarction, and 48.5% had died [4]. Although it is
frequently undiagnosed [1], it has been estimated that
4.3% of the United States (US) population 40 years and
older has PAD [5]. A similar prevalence of PAD has been
found in Western Europe, with population studies esti-
mating the prevalence between 4–8% [6-9].
Predominantly due to the functional limitations caused
by claudication [10,11], patients with PAD report signifi-
cantly lower health-related quality of life compared with
the general population on every Short Form-36 (SF-36)
domain [12]. Similarly, Leicht et al. (2010) reported phys-
ical SF-36 scores (physical component summary (PCS) =Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion norm of 50 [13].
Aside from the impact on patient health-related qual-
ity of life, PAD also poses an economic burden from a
societal perspective. In the US, PAD was associated with
an increase in hospitalizations by 0.32 times per year [14].
Indeed, PAD-related hospitalizations, most frequently due
to either stroke or MI, were the largest contributors of
PAD-related costs per patient (nearly 75% of total costs),
which summed to nearly $6,000 per patient per year [14].
More recent estimates have found similar vascular-related
hospitalization costs, with per-patient biennial costs ran-
ging from $7,000 for patients with a history of claudica-
tion to $10,430 for patients with revascularization [15].
Costs in the European Union (EU) are also high. Two-
year vascular-related hospitalization costs for patients with
PAD were €3182 in France and €2724 in Germany [16].
Because of the functional limitations associated with clau-
dication and ischemia, it is generally thought that PAD is
also associated with significant work loss [17]. However,
the extent of this relationship is not well known.
The objective of the current study was to further this
line of research to better understand the burden that
PAD poses from both a health-related quality of life and
economic perspective. Although health-related quality of
life and health utility values are often used as endpoints in
studies assessing PAD treatments [18-21] or as a predictor
or associated factor of physical functioning [10,11,13,22,23],
less is known about the effect of PAD on the health-related
quality of life of general PAD samples in Europe or the
US. Similarly, very little is known about the effect of PAD
on rates of work productivity loss. The generalizability of
the existing studies is also questionable since few, if any,
attempts were made to recruit samples from a broad
population. The aim of the current study was to address
these gaps by investigating the association between PAD
and health-related quality of life, work productivity loss,
and healthcare resource use, using a large, nationally-
representative (with respect to age and gender) data source
for both the 5EU (i.e., France, Germany, Italy, Spain, and
the UK) and the US.
Methods
Data source
Data were obtained from the 2010 5EU National Health
and Wellness survey (NHWS), which included partici-
pants from France, Germany, Italy, Spain, and the UK
(N = 57,805), as well as the 2010 US NHWS (N =
75,000). The NHWS is an annual, cross-sectional, self-
administered Internet survey administered to a sample
of adults who were identified through a web-based con-
sumer panel (i.e., a pre-recruited sample of adults who
agree to participate in survey research including, but not
limited to, the NHWS). Members of the panel are recruitedthrough opt-in emails, co-registration with panel partners,
e-newsletter campaigns, and online banner placements. All
panel members (over two million in the US and 5EU) ex-
plicitly agreed to join the panel, registered through unique
email addresses, and completed in-depth demographic re-
gistration profiles. The NHWS is just one of many poten-
tial surveys that any given panel member might be invited
to complete.
In all countries, a stratified random sampling frame
was implemented to ensure that the distribution of age,
gender and ethnicity (US only) of the NHWS sample
matched that of the respective countries according to
either the International Database of the Census (5EU)
or the US Census (United States Census Bureau, 2011).
More specifically, those governmental sources were used
to obtain the proportions of various demographic groups
(e.g., the proportion of the total adult population which
was 18–29 years old and male) among the adult population
of each country. All panel members were then categorized
into these demographic subgroups and were randomly
sampled to complete the NHWS in such a way that the
above mentioned demographic characteristics of the final
NHWS matched those of each country’s population. All
participants from 5EU (N = 57,805) and US (N = 75,000)
NHWS databases were included in the analyses.
Participants who completed the NHWS received com-
pensation in the form of points, which could be redeemed
for small prizes or entered into a drawing. All participants
provided informed consent and the study was approved by
Essex Institutional Review Board, Inc (Lebanon, NJ, USA;
5EU Approval reference number: KH-NHWS-EU2010; US
Approval reference number: CHS-NHWS-US2010-21105).




PAD diagnosis All participants in the NHWS were asked
whether they had ever been diagnosed with PAD by a
physician. Those who responded affirmatively were con-
sidered to have PAD while all others were considered not
to have PAD. No other inclusion or exclusion criteria were
applied.
Outcome measures
Health-related quality of life The Medical Outcomes
Study 12-Item Short Form Survey Instrument (SF-12v2),
a multipurpose, generic health-related quality of life
instrument comprised of 12 questions [26], was adminis-
tered in the survey. The SF-12v2 items are used to generate
two health-related quality of life summary scores: the phys-
ical component summary (PCS) and mental component
summary (MCS) scores, each of which are normed to the
population (a mean of 50 and a standard deviation of 10).
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health state utility (using the Short Form-6D, or SF-6D,
classification). The SF-6D classification is a method to cal-
culate a preference-based single index for health using gen-
eral population values, which varies (conceptually) from 0
to 1 with higher scores indicating a better health state [27].
As is standard for applying the SF-6D classification, UK
weights were applied to create health utility values.
Work productivity Work productivity was assessed using
the Work Productivity and Activity Impairment-General
Health (WPAI-GH; http://www.reillyassociates.net/WPAI_
General.html) questionnaire, a 6-item validated instrument
which consists of four metrics: absenteeism (the percent-
age of work time missed because of one’s health in the past
seven days), presenteeism (the percentage of impairment
experienced while at work in the past seven days because
of one’s health), overall work productivity loss (an overall
impairment estimate that is a combination of absenteeism
and presenteeism), and activity impairment (the percent-
age of impairment in daily activities because of one’s health
in the past seven days) [28]. Only participants who
reported being employed full-time or part-time provided
data for absenteeism, presenteeism, and overall work im-
pairment percentages. All participants provided data for
activity impairment.
Healthcare resource use Healthcare resource use was
defined by the number of healthcare provider visits,
the number of emergency room (ER) visits, and the
number of times hospitalized in the past six months.
All measures were reported by the participant. Re-
source use events were from all causes and were not
specific to PAD.
Covariates
Demographics and health characteristics Baseline dif-
ferences between those with and without PAD were ex-
amined for age, gender (male or female), ethnicity (for
US analyses only; non-Hispanic white, non-Hispanic black,
Hispanic, or other), education (university degree vs. less
than university degree), household income (5EU analyses:
below country-specific median, above country-specific me-
dian, or decline to answer; US analyses: <$25 K, $25 K
to < $50 K, $50 K to <$75 K, $75 K or more, or decline to
answer), alcohol use (currently drink vs. do not currently
drink), exercise behavior (currently exercise vs. do not cur-
rently exercise) and comorbidities (defined as the presence
or absence of the following comorbidity clusters, as de-
scribed in Additional file 1: cancer, gastrointestinal disease,
infectious disease, arthritis, psychiatric disease, respiratory
disease, renal disease, liver disease, diabetes, cardiovas-
cular disease, and cerebrovascular disease). Comorbidi-
ties were also assessed using the Charlson comorbidityindex (CCI) which is a single index score measuring the
overall comorbidity burden of a patient [29]. Partici-
pants were also asked to provide their height and weight
which was then used to calculate body mass index
(BMI; underweight, normal, overweight, obese, or de-
cline to provide weight).
Analyses
All analyses were conducted separately for the 5EU and
US. Descriptive statistics were used to summarize partici-
pant demographics, health behaviors, comorbid conditions
and patient reported outcomes. Differences in these factors
between participants with and without PAD (using all par-
ticipants from each respective NHWS) were assessed using
t-tests for continuous variables and chi-square tests for cat-
egorical variables. Due to a large imbalance with respect to
mean age between disease groups, we also conducted a 1-
to-1 hard match to minimize potential bias with respect to
measured outcomes. As such, each participant with PAD
was randomly matched to a single respondent of the same
age without PAD from the full survey cohort, and similar
analyses were repeated based on this sample.
Regression modeling was conducted to assess adjusted
differences in least square means between participants
with PAD and the age-matched group without PAD for all
patient reported outcomes. MCS, PCS, and health utilities
were examined using a general linear model; WPAI scores
and resource use variables were assessed using a general-
ized linear model (specifying a log-link function and a
negative binomial distribution due to overdispersion). All
regression analyses included the following covariates: gen-
der, education level, BMI, smoking, drinking and exercise
status, and comorbid conditions.
Health utilities were also assessed by individual 5EU
countries. Unlike the overall 5EU analyses, 1:1 hard match-
ing on age was not performed at the individual country
level due to challenges associated with smaller sample sizes.
However, age was added as a covariate in the regression
models.
For all regression models (these are hereafter referred
to “adjusted analyses”), adjusted means were reported.
Adjusted means represent the predicted value for the
outcome (separately for participants with and without
PAD), assuming all covariates are set at the sample mean.
For the general linear models, adjusted means were calcu-
lated using a least-squares algorithm; for the generalized
linear models, adjusted means were calculated using a
maximum likelihood algorithm and exponentiated to re-
adjust the means to the original metric (rather than the
log of the original metric).
Results
A total of 743 participants (1.29%) in the 5EU, and 777
participants (1.04%) in the US self-reported a diagnosis
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fered between these participants and those not reporting
a diagnosis of PAD (Table 1). In both the 5EU and US,
those diagnosed with PAD were significantly older and
less likely to have a university or college degree, have an
above median income, be currently employed, currently
consume alcohol, and to regularly exercise (all p < .05).
These patients were also significantly more likely to be
obese, to currently smoke and they had a greater comor-
bidity burden as indicated by the CCI (all p < .05). In
addition, all comorbidity clusters were significantly more
prevalent among those with PAD than those without
PAD in both regions (all p < .05). The only observed dif-
ference between the 5EU and the US was with regard toTable 1 Demographic, health characteristic, and comorbidity































*PAD and no PAD groups differ within region, p < .05.gender. In the 5EU, there was no difference between the
proportion of males with and without PAD (47.2% vs.
48.6%). However, in the US there were significantly more
males with PAD than without the disease (59.5% vs.
48.1%, p < .05).
Health outcomes of interest (i.e., health-related quality
of life, work productivity, activity impairment, and health-
care resource use), were also similar between the two re-
gions. Patients with PAD in the 5EU and the US reported
significantly lower health utilities and lower mental and
physical component summary scores compared with pa-
tients without PAD (all p < .05) (Table 2). These differ-
ences remained significant in adjusted analyses (Table 3).
Given its importance as a single indicator of health status,differences between those with and without PAD in the
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Table 2 Unadjusted mean patient-reported outcomes of those with and without PAD in the 5EU and United States
5EU
PAD No PAD (Age matched) No PAD
n = 743 n = 743 n = 57, 062
Mean SD Mean SD Mean SD
Mental component summary (MCS) score 43.44* 11.37 48.64 10.42 46.58 10.58
Physical component summary (PCS) score 37.57* 11.16 46.43 10.74 48.75 9.66
Health state utilities (SF-6D) 0.63* 0.12 0.73 0.14 0.73 0.13
Absenteeism % 12.08* 27.68 3.65 15.16 5.44 19.16
Presenteeism % 30.05* 27.42 13.77 21.03 15.84 22.8
Overall work impairment % 36.63* 33.33 16.26 24.73 19.39 27.69
Activity impairment % 46.54* 30.05 25.52 29.24 24.24 28.11
Number of physician visits 11.89* 13.66 5.66 6.24 5.34 7.37
Number of ER visits 0.40* 1.57 0.17 1.01 0.19 1.07
Number of hospitalizations 0.39* 1.54 0.12 0.62 0.13 1.16
US
PAD No PAD (Age matched) No PAD
n = 777 n = 777 n = 74,223
Mean SD Mean SD Mean SD
Mental component summary (MCS) score 45.51* 12.87 51.11 10 48.36 10.93
Physical component summary (PCS) score 31.77* 11.22 45.5 11.48 48.53 10.53
Health state utilities (SF-6D) 0.62* 0.14 0.76 0.14 0.75 0.14
Absenteeism % 12.80* 25.5 3.36 13.46 3.21 12.97
Presenteeism % 35.22* 30.46 13.99 22.95 14.37 22.63
Overall work impairment % 39.94* 34.34 15.62 25.3 16.12 25.11
Activity impairment % 56.67* 30.71 26.82 30.18 23.27 28.74
Number of physician visits 9.08* 9.63 4.98 6.61 3.86 5.87
Number of ER visits 0.65* 2.09 0.17 0.61 0.19 0.91
Number of hospitalizations 0.54* 1.56 0.12 0.44 0.11 0.91
*PAD group means differ from no PAD (age matched) group and no PAD group within region, p < .05.
Absenteeism, presenteeism, and overall work impairment were only asked among those who were currently employed.
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in 5EU (Figure 1). Within each country, those with PAD
reported significantly lower mean health utilities than
those without PAD; the unadjusted decrease in utilities,
i.e., the disutility ranged from 0.07 to 0.13. The adjusted
disutility ranged from 0.02 to 0.06.
In both the 5EU and US, among those participants
who reported being employed, those with PAD (EU
n = 231; US n = 170) reported significantly greater
levels of absenteeism, presenteeism, overall work im-
pairment and impairment in daily activities than par-
ticipants without PAD (EU n = 32,480; US n = 41,179)
(all p < .05) (Table 2). Likewise, the number of physician
visits, hospitalizations and number of emergency room
visits in the past six months were greater for those re-
porting PAD versus those without PAD in both regions
(all p < .05).In analyses adjusted for participant demographics and
health characteristics, all of the above-mentioned differ-
ences in health outcomes remained significant with the
exception of the number of emergency room visits (5EU
only), and presenteeism (US only). However, there was a
trend for participants with PAD to have utilized more
emergency room visits in the EU and to have a higher
rate of presenteeism in the US when compared to their
respective counterparts with no PAD (Table 3).
Discussion
The objective of the current study was to estimate the
burden of PAD across a wide array of health outcomes
in the 5EU and the US. Although a number of studies
have documented both the health-related quality of life
effects of PAD along with its direct costs [12-14], these
studies have often failed to adjust for demographics and
Table 3 Adjusted mean patient-reported outcomes of those with and without PAD in the 5EU and United States
5EU US
PAD No PAD PAD No PAD
n = 743 n = 743 n = 777 n = 777
Adjusted mean Adjusted mean Adjusted mean Adjusted mean
Mental component summary (MCS) score 45.14* 46.95 47.71* 48.91
Physical component summary (PCS) score 39.77* 44.23 35.10* 42.18
Health state utilities (SF-6D) 0.66* 0.70 0.66* 0.72
Absenteeism % 7.68* 3.39 6.05* 1.58
Presenteeism % 23.37* 14.23 18.35 13.46
Overall work impairment % 28.68* 16.83 23.89* 14.26
Activity impairment % 38.27* 27.48 41.88* 29.20
Number of physician visits 9.31* 6.18 6.79* 5.49
Number of ER visits 0.24 0.16 0.35* 0.14
Number of hospitalizations 0.25* 0.11 0.37* 0.20
*PAD and no PAD groups differ within region, p < .05.
Adjusted means represent the predicted value for the outcome (separately for patients with PAD and age-matched patients without PAD), assuming all covariates
are set at the sample mean. Covariates included gender, education level, BMI, smoking, drinking and exercise status, and comorbid conditions.
Absenteeism, presenteeism, and overall work impairment were only asked among those who were currently employed.
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fect of PAD on patient related health outcomes. Further,
many of these studies utilized convenience samples and
it remains unclear what the overall PAD burden would
be using a data source that is nationally representative
with regard to age and gender. Finally, although direct
costs have been previously studied, the extent to which






























Figure 1 Unadjusted and adjusted health state utility differences betwnot been previously investigated. In this study of 5EU
and US patients, those who reported being diagnosed
with PAD reported significantly worse health-related
quality of life, greater work and activity impairment,
and greater healthcare resource use compared to those
without PAD, and these differences remained after












een those with and without PAD by 5EU country.
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substantial health-related quality of life decrement among
those diagnosed with PAD. Indeed, our adjusted physical
component summary score mean for those with PAD in
the 5EU (39.77) was over one standard deviation below
the population mean of 50, consistent with what has been
reported in previous studies [13]. Across both regions,
the adjusted incremental differences between patients
with and without PAD are also noteworthy as both
physical component summary score and health utility
means exceeded cutoff values for what could be consid-
ered clinically-relevant differences (3 and 0.03 points,
respectively, based on pooled estimates from various
therapeutic areas) [26,30]. This finding highlights the
extent to which PAD can exert a clinically-meaningful
effect on even generic assessments of health status.
Given the mean age of patients affected by PAD (58 years
for the 5EU and 62 years for the US), it is not surprising
that less than a third were still active in the labor force.
Nevertheless, as suggested by prior research [17], patients
with PAD reported significantly more work-related impair-
ments than those without PAD, even after accounting for
other demographic and health characteristics. In the ad-
justed analysis, approximately 25% of work time was missed
either due to health-related absences or reduced productiv-
ity because of health (i.e., overall work impairment).
Although direct cost analyses were not part of the
current study, the number of patient-reported resource
utilization events was assessed. Past literature has sug-
gested that the majority of PAD-related direct costs are
due to the increased rate of hospitalizations [14], how-
ever, we also found a greater number of physician visits
in the past six months for patients in the 5EU.
The results in the US were similar to those in Europe
with respect to directionality and statistical significance.
As with prior research [13], the mean adjusted physical
component summary score (35.10) was more than one
standard deviation below the population norm of 50.
Work impairment was generally worse for those with
PAD (with the exception of presenteeism), and the size
of these adjusted effects was consistent with what was
observed in the 5EU. Despite the older patient popula-
tion, these results indicate that PAD is associated with a
substantial increase in indirect costs. In the adjusted ana-
lysis, ER visits and hospitalizations were more frequent in
the US than in the 5EU in absolute numbers, perhaps
reflecting healthcare system differences. However, on a
relative level (the percentage increase difference between
patients with PAD versus controls) the effects were com-
parable between the regions.
Limitations
Several limitations of this study should be noted. All data
were self-reported including diagnosis of PAD and othercomorbid conditions. Given the relatively high number of
patients who remain undiagnosed with PAD, it is possible
that some degree of misclassification may have occurred.
As a result, the differences between groups may have been
underestimated, though future research using more ob-
jective means of classifying patients would be necessary to
determine the extent of any underestimation observed
here. Work productivity and resource use variables were
also self-reported and may have been subject to recall
biases and other forms of measurement error. Because the
SF-12v2 was used as the measure of health-related quality
of life, only UK-specific utility weights were available to
convert item scores to health utilities. Health utilities
assessed with another instrument with country-specific
weighting (e.g., EuroQoL-5D), might produce different
effects. Although an attempt was made to rule out alter-
native explanations (demographics, health behaviors,
comorbidities), it is possible that unmeasured variables
might further explain the association between PAD and
health-related outcomes. 5EU countries were pooled for
analyses of work productivity and healthcare resource
for the sake of sample size and brevity, yet this may have
hidden underlying heterogeneity across these countries.
The NHWS is representative of each country’s total adult
population with respect to age and gender (and race/eth-
nicity in the US) but the PAD specific sample used here
may differ in ways other than demographics from the
PAD population which could influence the generalizability
of the findings. For example, those participating in the
NHWS may be higher functioning (as they are able to
complete a survey) and therefore their outcomes might be
underestimating the true effect of PAD. Additional studies
should explore these research questions in other coun-
tries, to determine the universality of the observed effects.
Conclusions
Collectively, these results suggest that PAD imposes a
significant burden on patients in both the 5EU and the
US. Patients with PAD exhibited poorer mental and
physical health-related quality of life, greater healthcare
resource use, and greater impairment in work and daily
activities. Improved management of PAD may improve
patient health-related quality of life and reduce the eco-
nomic impact from a societal perspective.
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